Sofosbuvir-Velpatasvir · Epclusa, Sofosbuvir And Velpatasvir

What is Sofosbuvir-Velpatasvir?

Sofosbuvir-velpatasvir is a fixed-dose combination of sofosbuvir, a nucleotide analog that inhibits the HCV NS5B polymerase, and velpatasvir, an inhibitor of the HCV NS5A protein. It is studied in chronic hepatitis C infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Epclusa, Sofosbuvir And Velpatasvir, Vosevi, (SOF/VEL)

Drug type

Small molecule

Targets

HCV NS5B polymerase, HCV NS5A protein

Mechanism

Inhibitor of HCV NS5B polymerase and HCV NS5A protein

Therapy area

Infectious disease

Developer

Gilead Sciences, Inc.

In trials of

AVIR

FDA status

Approved as Epclusa, Sofosbuvir And Velpatasvir, Vosevi, NDA209195 · FDA label

✅ FDA-approved uses

• Chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection (Sofosbuvir And Velpatasvir)
• Chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection (Epclusa)

From the indications section of the FDA label (version of Mar 6, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis CHEPATITIS C VIRUS CHRONIC INFECTIONHepatitis C Virus InfectionHepatitis C, Chronic

Sources

• FDA label (DailyMed)
• FDA label Vosevi (2025-07-14), indications
• FDA label Sofosbuvir And Velpatasvir (2025-03-06), indications
• FDA label Epclusa (2024-06-05), indications
• ClinicalTrials.gov NCT06868264
• ClinicalTrials.gov NCT07037277

Updated Oct 11, 2026.